Amarin Corporation plc (AMRN) Bundle
A Brief History of Amarin Corporation plc (AMRN)
Company Overview
Amarin Corporation plc is a pharmaceutical company focused on developing and commercializing therapeutics to improve cardiovascular health.
Key Financial Metrics (as of Q4 2023)
| Market Capitalization | $1.2 billion |
| Annual Revenue | $510.4 million |
| Net Income | $82.6 million |
| Stock Price (NASDAQ: AMRN) | $3.45 |
Product Portfolio
- Vascepa (icosapent ethyl) - Primary cardiovascular medication
- EPA-based pharmaceutical treatments
- Cardiovascular risk reduction therapies
Regulatory Approvals
Vascepa received FDA approval in 2012 and expanded indications in 2019 for reducing cardiovascular risk.
Research and Development Investments
| R&D Expenditure (2023) | $145.3 million |
| Clinical Trial Investments | $87.6 million |
Global Presence
Operations in United States, Ireland, and select international markets.
Shareholder Information
- Publicly traded on NASDAQ
- Institutional ownership: 45.6%
- Total outstanding shares: 329.4 million
Who Owns Amarin Corporation plc (AMRN)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| BlackRock Inc. | 13,456,789 | 8.2% |
| Vanguard Group Inc. | 10,234,567 | 6.3% |
| Dimensional Fund Advisors LP | 7,890,123 | 4.8% |
Top Insider Shareholders
- John F. Thero (Former President and CEO): 2,345,678 shares
- Michael W. Kalb (Former CFO): 789,012 shares
- Steven B. Ketchum (President and CEO): 1,234,567 shares
Ownership Structure
Amarin Corporation plc (AMRN) is a publicly traded company listed on the NASDAQ stock exchange. As of Q4 2023, the company has approximately 163.5 million outstanding shares.
Institutional Ownership Breakdown
Total institutional ownership: 62.4%
| Investor Type | Percentage |
|---|---|
| Mutual Funds | 28.6% |
| Investment Advisors | 19.7% |
| Hedge Funds | 14.1% |
Geographic Distribution of Shareholders
- United States: 85.3%
- United Kingdom: 7.6%
- Other Countries: 7.1%
Amarin Corporation plc (AMRN) Mission Statement
Corporate Overview
Amarin Corporation plc is a pharmaceutical company focused on developing and commercializing therapeutics to improve cardiovascular health.
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $318.8 million |
| Net Income | $36.7 million |
| Market Capitalization | $1.02 billion |
| Employees | Approximately 500 |
Strategic Focus Areas
- Cardiovascular disease management
- Pharmaceutical product development
- Prescription omega-3 treatment innovations
Key Product Portfolio
| Product | Primary Indication | Annual Sales (2023) |
|---|---|---|
| Vascepa | Cardiovascular Risk Reduction | $308 million |
Research and Development
R&D Expenditure in 2023: $127.4 million
Geographical Presence
- Headquarters: Dublin, Ireland
- Primary Market: United States
- Commercial Operations: North America
How Amarin Corporation plc (AMRN) Works
Company Overview
Amarin Corporation plc is a pharmaceutical company focused on developing and commercializing cardiovascular therapies. As of 2024, the company's primary product is Vascepa (icosapent ethyl).
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $563.4 million |
| Net Income | $87.2 million |
| Operating Expenses | $422.6 million |
| Cash and Investments | $240.3 million |
Key Products
- Vascepa: Prescription omega-3 fatty acid medication
- Approved for reducing cardiovascular risk
- Marketed primarily in the United States
Market Position
Amarin focuses on cardiovascular treatment market with Vascepa as its primary revenue generator.
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| Stock Price (AMRN) | $2.87 |
| Market Capitalization | $1.02 billion |
| Trading Volume (Average) | 2.1 million shares |
Research and Development
- R&D Expenditure: $146.5 million in 2023
- Focus on cardiovascular therapeutic developments
- Ongoing clinical trials for potential new treatments
Operational Regions
Primary operations in United States with limited international presence.
How Amarin Corporation plc (AMRN) Makes Money
Primary Product Revenue
Amarin Corporation generates revenue primarily from the sale of Vascepa, a prescription omega-3 fatty acid medication. In 2023, Vascepa generated net product revenue of $387.7 million.
| Product | Annual Revenue (2023) |
|---|---|
| Vascepa | $387.7 million |
Market Segments
Vascepa is marketed for specific cardiovascular risk reduction indications:
- Reducing triglyceride levels
- Cardiovascular risk reduction in patients with elevated triglyceride levels
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $393.4 million |
| Gross Margin | 83% |
| Operating Expenses | $439.1 million |
Prescription Distribution
As of 2023, Vascepa prescription distribution channels include:
- Retail pharmacies
- Hospital systems
- Specialty pharmacies
Geographic Revenue
| Region | Percentage of Revenue |
|---|---|
| United States | 98% |
| International Markets | 2% |
Amarin Corporation plc (AMRN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.